**Author Information** An event is serious (based on the ICH definition) when the patient outcome is:\* death\* life-threatening\* hospitalisation\* disability\* congenital anomaly\* other medically important event

A 42-year-old woman developed Stevens-Johnson syndrome (SJS) following an off-label treatment with hydroxychloroquine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

The woman presented with fever and dry cough for the duration of 2 days. Her medical history was significant for contacting someone with similar symptoms. Based on the clinical and laboratorial findings, SARS-CoV-2 infection was diagnosed. She started receiving an off-label treatment with hydroxychloroquine 200mg twice daily \[*route not stated*\] concomitantly with paracetamol \[acetaminophen\] for fever. After 2 days of the hydroxychloroquine therapy, she presented with a pruritic erythematous maculopapular rash and flat atypical targets, which started from the distal of upper extremities rapidly involved the entire body and torn blisters that were only be seen as ulcers on orolabial area. Additionally, she had a genital mucosal involvement. The Nikolsky sign was also found to be positive. Based on these findings, a diagnosis of SJS due to hydroxychloroquine was made.

The woman was hospitalised, and her therapy with hydroxychloroquine was discontinued. Subsequently, she started receiving an off-label therapy with lopinavir/ritonavir 400mg twice daily for SARS-CoV-2 infection in the hospital. She was treated with diphenhydramine and loratadine for SJS. She was discharged after 5 days with a non-pruritic scalded skin on the distal of upper extremities.
